Literature DB >> 9756471

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

A U Neumann1, N P Lam, H Dahari, D R Gretch, T E Wiley, T J Layden, A S Perelson.   

Abstract

To better understand the dynamics of hepatitis C virus and the antiviral effect of interferon-alpha-2b (IFN), viral decline in 23 patients during therapy was analyzed with a mathematical model. The analysis indicates that the major initial effect of IFN is to block virion production or release, with blocking efficacies of 81, 95, and 96% for daily doses of 5, 10, and 15 million international units, respectively. The estimated virion half-life (t1/2) was, on average, 2.7 hours, with pretreatment production and clearance of 10(12) virions per day. The estimated infected cell death rate exhibited large interpatient variation (corresponding t1/2 = 1.7 to 70 days), was inversely correlated with baseline viral load, and was positively correlated with alanine aminotransferase levels. Fast death rates were predictive of virus being undetectable by polymerase chain reaction at 3 months. These findings show that infection with hepatitis C virus is highly dynamic and that early monitoring of viral load can help guide therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756471     DOI: 10.1126/science.282.5386.103

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  545 in total

1.  Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month.

Authors:  A Magalini; M Puoti; V Putzolu; E Quiros-Roldan; M A Forleo; S Rossi; S Zaltron; A Spinetti; B Zanini; A Zonaro; R Solfrini; G Carosi
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

Review 2.  Translational control of viral gene expression in eukaryotes.

Authors:  M Gale; S L Tan; M G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

Review 3.  Quantitative molecular analysis of virus expression and replication.

Authors:  M Clementi
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

Review 4.  Mechanisms of immune escape in viral hepatitis.

Authors:  W Rosenberg
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

5.  Estimating relative fitness in viral competition experiments.

Authors:  A F Marée; W Keulen; C A Boucher; R J De Boer
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Molecular biology of liver disorders:the hepatitis C virus and molecular targets for drug development.

Authors:  Howard J Worman; Feng Lin
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

7.  HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing?

Authors:  R A Arnaout; M A Nowak; D Wodarz
Journal:  Proc Biol Sci       Date:  2000-07-07       Impact factor: 5.349

8.  Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis.

Authors:  Naoki Fujita; Mamoru Nakanishi; Jun Mukai; Yuuji Naito; Takafumi Ichida; Masahiko Kaito; Toshikazu Yoshikawa; Yoshiyuki Takei
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

9.  B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia.

Authors:  G Lake-Bakaar; I Jacobson; A Talal
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

10.  Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons.

Authors:  Ju-Tao Guo; Qing Zhu; Christoph Seeger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.